Decreased Cardiotoxicity With Infusional Doxorubicin
OncoPharm
English - October 21, 2021 16:37 - 14 minutes - 12.1 MB - ★★★★★ - 161 ratingsScience Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Adjuvant Abemaciclib
Next Episode: Adjuvant Atezo, Palbo-PPI Interaction? And More
We return to our Landmarks of OncoPharm series to dive deep into an article that provided some of our foundational understanding of how anthracycline cardiotoxicity risk is influenced by rate of administration.
Link: https://pubmed.ncbi.nlm.nih.gov/2910423/